Ligand raises 2026 adjusted EPS guidance to $9.50-$9.75 while targeting ~$200M annual capital deployment

Resumen del corpus

Ligand Pharmaceuticals raised its adjusted EPS guidance for 2026 to $9.50-$9.75 and projects an annual capital deployment of approximately $200 million. The CEO and Director, Todd Davis, noted that the third quarter was significant, with royalty revenues growing 51% year-over-year to about $70 million.